Trial reportBlood neoplasia2026
Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Trial report in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
Abstract
Functional small-molecule screening of primary acute myeloid leukemia (AML) samples identified ex vivo synergy between the JAK1/2 inhibitor, ruxolitinib (Rux), and venetoclax (Ven) in newly diagnosed and relapsed/refractory (R/R) AML. This motivated a phase 1 multicenter trial to evaluate Rux + Ven in 30 patients with R/R AML. Patients had median age of 69 years and were heavily pretreated (40% with ≥3 previous lines, 43% with previous Ven failure). Rux (30 mg twice daily) and Ven (400 mg once daily) were well tolerated without dose-limiting toxicities. Median duration of therapy was 55 days. Over 2 cycles of Rux + Ven, clinical response rate was 20% and composite complete remission (CR) rate was 10%. Median survival was 3.7 months, with 23% alive at 1 year. There were 2 exceptional responders, including a patient who remained in CR/CR with incomplete hematologic recovery for nearly 4 years after hypomethylating agent + Ven failure. CD56 expression on blasts was significantly associated with lack of clinical response (odds ratio, 0.09;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.